By Frank Prenesti
Date: Thursday 15 Dec 2022
LONDON (ShareCast) - (Sharecast News) - The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.
Both companies said they would continue to work with the FDA to facilitate the completion of the agency's review.
Email this article to a friend
or share it with one of these popular networks:
Currency | US Dollars |
Share Price | $ 99.18 |
Change Today | $ -0.68 |
% Change | -0.68 % |
52 Week High | $132.96 |
52 Week Low | $96.31 |
Volume | 14,031,186 |
Shares Issued | 2,531.63m |
Market Cap | $251,087m |
Beta | 0.19 |
RiskGrade | 92 |
Time | Volume / Share Price |
16:00 | 2,776,460 @ $99.18 |
15:59 | 100 @ $99.14 |
15:59 | 430 @ $99.18 |
15:59 | 100 @ $99.17 |
15:59 | 100 @ $99.23 |
You are here: research